Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report in NEJM. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial, sponsored by NIAID. The randomized, controlled trial enrolled hospitalized adults with COVID-19 with evidence of lower respiratory tract involvement. Investigators found that remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen.